ClinicalTrials.gg
CompletedNCT06491550Updated Jul 4, 2025

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants

A Phase 1 interventional study of AZD4144- Part A and Placebo- Part A in Healthy Participants, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144

Read the detailed description

This is a Phase I, randomized study in healthy participants and consists of 3 parts; Part A, Part B and Part C. Part A and B are single-blind, placebo-controlled with single ascending dose (SAD) and multiple ascending dose (MAD) sequential group design, respectively. Part C is an open-label, 2-period, 2-sequence, cross-over design study. Part A and B of the study will assess the safety, tolerability, PK, and PD of AZD4144 solution for infusion compared with placebo while Part C will investigate the possibility of DDI between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144

The study will comprise of:

  • A screening period of maximum 28 days.
  • A residential period which lasts from,

    • Day -1 to Day 4 (single dose on Day 1) for Part A
    • Day -1 to Day 15 (dosed on days 1, 4-12) for Part B
    • Day -1 to Day 3 (dose on Day 1) and Day 9 to Day 12 (dose on Day 10) for Part C
  • A final follow-up visit,

    • On Day 10+3 for Part A
    • On Day 20+3 for Part B and C
02

Conditions studied

  • Healthy Participants

Keywords

  • Pharmacokinetic (PK)
  • Pharmacodynamic (PD)
  • Drug-drug interaction (DDI)
  • Single ascending dose (SAD)
  • Multiple ascending dose (MAD)
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
  • Females of must not be lactating and if heterosexually active must agree to use an approved method of highly effective .
  • Females of non-childbearing potential must be confirmed at the Screening Visit.
  • Sexually active fertile male participants with partners of childbearing potential must adhere to the contraception methods.
  • Have a between 18 and 32 kg/m2 inclusive at both Screening and Admission and weigh at least 45 kg at Screening.
  • For healthy Japanese cohorts (Part A2 and Part B2): healthy male and female participants are to be Japanese, defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan.
  • For healthy Chinese cohort (Part A3): healthy male and female Chinese participants for whom both parents and all grandparents are Chinese and not lived outside of China for more than 10 years.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma.
  • Clinically significant serious active and chronic infections.
  • Any history or evidence of TB (active or latent).
  • Known history of primary immunodeficiency (congenital or acquired) or an underlying condition that predisposes to infection.
  • Bacillus Calmette Guérin vaccine within one year prior to signing the ICF.
  • Any abnormal laboratory values at the Screening Visit or on Admission to the Clinical Unit.
  • Any positive result on Screening for serum surface antigen (HBsAg), anti-Hepatitis B core (HBc), antibody, or (HIV).
  • Any clinically important abnormalities in .
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity.
  • Known hypersensitivity to furosemide and rosuvastatin (for Part C only)
  • History of alcohol abuse or excessive intake of alcohol or current smokers or those who have smoked or used nicotine products.
  • Use of drugs with enzyme inducing properties or of any prescribed or nonprescribed medication or of systemic hormonal .
  • Clinical signs and symptoms consistent with COVID-19.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Part A1-Cohort 1

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144- Part A

  • Experimental
    Part A1- Cohort 2

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144- Part A

  • Experimental
    Part A1-Cohort 3

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144- Part A

  • Experimental
    Part A2-Japanese cohort 1

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144- Part A

  • Experimental
    Part A2: Japanese Cohort 2

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144- Part A

  • Experimental
    Part A3-Chinese Cohort

    Participants will receive one single ascending dose of AZD4144.

    Drug: AZD4144- Part A

  • Experimental
    Part B1- Cohort 1

    Participants will receive multiple ascending doses of AZD4144.

    Drug: AZD4144- Part B

  • Experimental
    Part B1- Cohort 2

    Participants will receive multiple ascending doses of AZD4144.

    Drug: AZD4144- Part B

  • Experimental
    Part B1- Cohort 3

    Participants will receive multiple ascending doses of AZD4144.

    Drug: AZD4144- Part B

  • Experimental
    Part B2- Japanese Cohort

    Participants will receive multiple ascending doses of AZD4144.

    Drug: AZD4144- Part B

  • Experimental
    Part C Cohort- Treatment C1

    Participants will receive rosuvastatin and furosemide.

    Drug: Rosuvastatin and Furosemide- Part C

  • Experimental
    Part C cohort- Treatment C2

    Participants will receive rosuvastatin, furosemide, and AZD4144.

    Drug: Rosuvastatin, Furosemide, and AZD4144 Part C

  • Placebo comparator
    Part A1- Placebo

    Participants will receive matching placebo.

    Drug: Placebo- Part A

  • Placebo comparator
    Part A2- Placebo

    Participants will receive matching placebo.

    Drug: Placebo- Part A

  • Placebo comparator
    Part A3- Placebo

    Participants will receive matching Placebo.

    Drug: Placebo- Part A

  • Placebo comparator
    Part B1- Placebo

    Participants will receive matching Placebo.

    Drug: Placebo- Part B

  • Placebo comparator
    Part B2- Placebo

    Participants will receive matching Placebo.

    Drug: Placebo- Part B

Interventions

  • Part A: Participants will be administered a single dose of AZD4144 on Day 1 via Intravenous (IV) infusion.

  • DrugPlacebo- Part A

    Part A: Participants will be administered a single dose of placebo on Day 1 via IV infusion.

  • Part B: Participants will be administered a single dose of AZD4144 on Day 1 and Day 12 via IV infusion. Participants will be administered multiple doses of AZD4144 from Day 4 to Day 11 via IV infusion.

  • DrugPlacebo- Part B

    Part B: Participants will be administered a single dose of placebo on Day 1 and Day 12via IV infusion. Participants will be administered multiple doses of placebo from Day 4 to Day 11 via IV infusion.

  • DrugRosuvastatin and Furosemide- Part C

    Participants will be administered a single oral dose of 10 mg Rosuvastatin and 1 mg Furosemide.

  • DrugRosuvastatin, Furosemide, and AZD4144 Part C

    Participants will be administered a single oral dose of 10 mg Rosuvastatin, 1 mg Furosemide and a single dose of AZD4144 via IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) (Part A and Part B)

    To assess the safety and tolerability of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses in healthy participants.

    Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3.

  2. Area under plasma concentration-time curve from time 0 to infinity (AUCinf) (Part C)

    To evaluate the effect of AZD4144 on the PK of rosuvastatin and furosemide in healthy participants.

    Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.

  3. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) (Part C)

    To evaluate the effect of AZD4144 on the PK of rosuvastatin and furosemide in healthy participants.

    Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.

  4. Maximum observed drug concentration (Cmax) (Part C)

    To evaluate the effect of AZD4144 on the PK of rosuvastatin and furosemide in healthy participants.

    Time frame: Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.

Secondary outcomes

  1. Cmax (Part A and Part B)

    To characterize the PK of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses.

    Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3

  2. AUClast (Part A and Part B)

    To characterize the PK of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses

    Time frame: Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3

  3. AUCinf (Part A)

    To characterize the PK of AZD4144 following IV administration of single (Part A) ascending doses.

    Time frame: Part A: Day 1 to Day 10+3

  4. Area under concentration-time curve in the dosing interval (AUCτ) (Part B only)

    To characterize the PK of AZD4144 following IV administration of multiple (Part B) ascending doses

    Time frame: Part B: Day 1 to Day 20+3

  5. Renal clearance of drug from plasma (CLR) (Part A and Part B)

    To characterize the PK of AZD4144 following IV administration of single (Part A) and multiple (Part B) ascending doses.

    Time frame: Part A: Day 1 to 3; Part B: Day 1, 12 and 20+3

  6. PD analysis: Levels of disease-specific biomarkers (Part A and Part B)

    To assess the effect of AZD4144 on levels of disease-specific biomarkers. (Part A and Part B)

    Time frame: Part A: Day -1 to 4; Part B: Day -1 to Day 1, Day 12 to Day 15

  7. Number of participants with adverse events (AEs) (Part C)

    To assess the safety and tolerability of AZD4144 in combination with rosuvastatin and furosemide in healthy participants.

    Time frame: Part C: Day 1 to Day 20+3

07

Study locations

2 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jun 2025, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 9, 2024
StartActual
Jul 15, 2024
Primary completionActual
Jun 11, 2025
CompletionActual
Jun 11, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06491550
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 9, 2024
Start date
Jul 15, 2024
Primary completion
Jun 11, 2025
Completion
Jun 11, 2025
Last update
Jul 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD4144

Start the discussion